CCHIO 2024丨Dr. Xiufeng Liu: Exploring the Clinical Potential of the “Cola Combination” from LEAP-002 to LEAP-012

2024.12.06
The era of immunotherapy has brought new hope to advanced hepatocellular carcinoma (HCC), with various targeted-immune combination therapies emerging as potential breakthroughs. However, the journey of the "Cola Combination"—pembrolizumab combined with lenvatinib—has been marked by mixed results. In the LEAP-002 trial, the combination showed negative results in the general population but positive outcomes in the Asian subgroup. The LEAP-012 trial further demonstrated the combination's efficacy when paired with transarterial chemoembolization (TACE) in intermediate-stage HCC. Yet, its precise role in clinical practice remains under discussion.
Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

2024.12.02
Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC treatment and improve patient outcomes. In this event, Oncology Frontier interviewed Dr. Yige Bao from West China Hospital of Sichuan University, who shared insights into personalized perioperative treatment of UTUC with ADC drugs and the hospital's clinical experiences.
The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma

The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma

2024.12.02
Urothelial carcinoma (UC) is one of the most common malignant tumors of the urinary system, encompassing bladder cancer, renal pelvic cancer, and ureteral cancer. Radiotherapy, as a critical treatment modality for tumors, has gained prominence in the comprehensive treatment of UC, offering hope for improved survival outcomes. During the 8th West China Urologic Oncology Academic Conference held in Chengdu, Oncology Frontier invited Dr. Hongzhen Li from Peking University First Hospital to share the latest advancements in radiotherapy for UC.
2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women？

2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women？

2024.12.02
The third week of every November marks World Antimicrobial Awareness Week (WAAW). This year, WAAW adopts the theme: "Educate, Advocate, Act," aiming to raise public awareness about antimicrobial drugs, advocate for their appropriate use, and encourage action to combat antimicrobial resistance (AMR). In response to this call, Oncology Frontier invited Dr. Pengfei Shen from West China Hospital of Sichuan University to provide an informative overview of female urinary tract infections (UTIs), exploring why women are more prone to these infections, common symptoms, frequently used antibiotics, and the importance of responsible medication use to prevent antibiotic resistance.
Dr. Jun Guo: Reflecting on Progress in Renal Cancer Treatment and Pioneering a New Era of Cellular Therapy for Metastatic Patients

Dr. Jun Guo: Reflecting on Progress in Renal Cancer Treatment and Pioneering a New Era of Cellular Therapy for Metastatic Patients

2024.11.25
Renal cancer is one of the three major malignancies in the urinary system, with advanced metastatic renal cancer having a poor prognosis and an overall five-year survival rate of less than 20%. Recent advances in targeted therapies and immunotherapies have led to significant improvements in treatment outcomes; however, for patients progressing beyond first-line therapies, the quest to extend survival remains an ongoing challenge. At the recently held 8th West China Uro-Oncology Tianfu Academic Conference, Dr. Jun Guo from Peking University Cancer Hospital shared insights into "Future Trends in Cellular Therapy for Renal Cancer," offering new hope for these patients. Following the conference, Oncology Frontier invited Professor Guo to provide further insights.
Dr. Kan Gong: Reflecting on Key Challenges and Hotspots in Renal Cancer Diagnosis and Treatment in China, Exploring New Frontiers in Translational Research | The 8th West China Uro-Oncology Tianfu Academic Conference

Dr. Kan Gong: Reflecting on Key Challenges and Hotspots in Renal Cancer Diagnosis and Treatment in China, Exploring New Frontiers in Translational Research | The 8th West China Uro-Oncology Tianfu Academic Conference

2024.11.25
Renal cancer is one of the three major malignancies in the urinary system. Early-stage renal cancer often presents with concealed symptoms, making it difficult to differentiate between benign and malignant tumors. Advanced renal cancer primarily relies on targeted or immunotherapy, yet the effectiveness of existing targeted drugs is low, and resistance tends to develop easily. Therefore, conducting targeted translational research based on clinical problems offers hope for improving the current state of renal cancer diagnosis and treatment in China. At the 8th West China Uro-Oncology Tianfu Academic Conference held in Chengdu, Oncology Frontier invited Dr. Kan Gong from the Institute of Urology at Peking University and the Department of Urology at Peking University First Hospital to share insights into the current state of renal cancer diagnosis and treatment in China, as well as the highlights of his team’s work in translational research.
Dr. Qiang Wei: International and Domestic Experts Discuss Annual Advances in Urological Oncology; Demonstrating MDT Applications to Drive Standardization in China | 8th West China Uro-Oncology Tianfu Academic Conference

Dr. Qiang Wei: International and Domestic Experts Discuss Annual Advances in Urological Oncology; Demonstrating MDT Applications to Drive Standardization in China | 8th West China Uro-Oncology Tianfu Academic Conference

2024.11.22
From November 4–10, 2024, the 8th West China Uro-Oncology Tianfu Academic Conference and the 10th Urological and Male Reproductive Oncology Annual Conference of the Sichuan Anti-Cancer Association were successfully held in Chengdu. This event shared the latest domestic and international advancements in clinical data, research findings, complex case discussions, and cutting-edge diagnostics and treatment. Following the conference, Oncology Frontier invited the conference chair, Dr. Qiang Wei from West China Hospital of Sichuan University, to discuss the highlights of the event, the development of urological oncology in China, and the value of multidisciplinary treatment (MDT).
ESMO 2024丨Dr. Dingwei Ye: Exciting Advances with EGFR/HER3 Dual-Antibody ADC, New Successes in Urologic Oncology

ESMO 2024丨Dr. Dingwei Ye: Exciting Advances with EGFR/HER3 Dual-Antibody ADC, New Successes in Urologic Oncology

2024.11.17
The 2024 European Society for Medical Oncology (ESMO) Congress was held from September 13 to 17 in Barcelona, Spain. During the event, multiple key studies in urologic oncology were highlighted. Dr. Dingwei Ye from Fudan University Shanghai Cancer Center presented preliminary findings on the safety, tolerability, and efficacy of BL-B01D1, a novel EGFR/HER3 dual-targeting antibody-drug conjugate (ADC), in patients with previously treated metastatic urothelial carcinoma (UC), garnering considerable attention. Urology Frontier invited Dr. Dingwei Ye to share major developments in urologic oncology from the congress, discuss new dual-targeted therapies for advanced UC, and highlight the Fudan University Shanghai Cancer Center’s progress in this area.